On April 29, 2026, the National Cancer Center in South Korea will host its 10th Cancer Science Forum under the theme “Medical AI Innovation and Challenge.” The event, scheduled to begin at 1:30 p.m. Local time at the National Cancer Prevention Screening Building’s 8th-floor International Conference Room, brings together medical professionals, researchers, and industry experts to examine the evolving role of artificial intelligence in oncology care.
According to official announcements from the National Cancer Center, the forum aims to address both the transformative potential and persistent challenges of integrating AI into cancer diagnosis, treatment planning, and healthcare delivery. Discussions will span technical innovation, clinical validation, data governance, and policy frameworks necessary for responsible AI adoption in medical settings.
The forum’s agenda reflects growing global interest in how AI systems — particularly multimodal models and large language model (LLM)-based applications — are reshaping precision medicine. As noted in promotional materials, recent advances allow AI to integrate genomic data, clinical records, and imaging inputs to support predictive modeling of treatment response, moving beyond basic image analysis toward more comprehensive clinical decision support.
Organizers emphasize that while AI offers significant promise in streamlining workflows and enabling personalized care, its real-world implementation raises critical questions about algorithmic transparency, bias mitigation, data standardization, and regulatory oversight. These themes will be explored across two main sessions during the half-day event.
The first session, titled “Medical AI Infrastructure and Platform Innovation,” will feature presentations on health data utilization through innovation zones, clinical validation platforms for AI tools, and LLM-driven AI agent systems. Speakers include representatives from the National Cancer Center’s National Cancer Data Center, Dongyang University Hospital, and Seoul National University Hospital.
The second session, “Medical AI in Practice and Future Strategy,” will focus on real-world applications, including AI’s role in aging populations, smart hospital digital transformation (DX to AX), and regulatory sandbox initiatives in information and communications technology. Contributors are expected from Severance Hospital, Samsung Medical Center, and the Korea Information and Communications Technology Association.
Following the presentations, a panel discussion will bring together speakers and experts to explore actionable pathways for accelerating AI adoption in clinical environments while addressing safety, equity, and institutional readiness.
Participation is open to healthcare providers, biomedical scientists, pharmaceutical and biotechnology professionals, and other stakeholders in the cancer care ecosystem. Attendance is free of charge, though those seeking continuing medical education credits through the Korean Medical Association may incur a nominal fee of 10,000 KRW for two accredited points.
Registration was open from March 30 to April 22, 2026, with both in-person and virtual attendance options available via Zoom for those who registered in advance. Organizers have advised attendees to consider public transportation due to potential parking limitations at the venue.
For further information, inquiries can be directed to the National Cancer Center’s Education and Training Team at 031-920-1952 or [email protected].
The forum underscores South Korea’s ongoing investment in advancing medical AI research and infrastructure, positioning the National Cancer Center as a key hub for dialogue between innovation and practical implementation in oncology.
As healthcare systems worldwide grapple with the integration of AI tools, events like this provide critical opportunities to align technological progress with clinical needs, ethical standards, and sustainable implementation strategies.
The next official update regarding the forum’s outcomes or future iterations of the Cancer Science Series has not yet been announced. Readers are encouraged to consult the National Cancer Center’s official website or press office for post-event summaries and recordings.
If you found this overview informative, please consider sharing it with colleagues interested in medical innovation or leaving a comment below to join the conversation.